scholarly journals Ramucirumab in patients with advanced hepatocellular carcinoma and elevated alpha‐fetoprotein: outcomes by treatment‐emergent ascites

2021 ◽  
Author(s):  
Masatoshi Kudo ◽  
Masafumi Ikeda ◽  
Peter R. Galle ◽  
Tatsuya Yamashita ◽  
Richard S. Finn ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Alpha Fetoprotein ◽  
Advanced Hepatocellular Carcinoma

Liver transplantation for hepatocellular carcinoma with portal vein tumor thrombosis

2021 ◽  
Vol 21 (2) ◽  
pp. 105-112
Author(s):  
Sang Jin Kim ◽  
Jong Man Kim
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Radiation Therapy ◽  
Portal Vein ◽  
Alpha Fetoprotein ◽  
Advanced Hepatocellular Carcinoma ◽  
Portal Vein Tumor Thrombosis ◽  
Donor Liver Transplantation ◽  
Tumor Thrombosis ◽  
Locoregional Therapies

Traditionally, liver transplantation for hepatocellular carcinoma with portal vein tumor thrombosis is not recommended. However, with recent developments in locoregional therapies for hepatocellular carcinoma, more aggressive treatments have been attempted for advanced hepatocellular carcinoma. Recently, various studies on locoregional therapies for downstaging followed by living donor liver transplantation reported inspiring overall survival and recurrence-free survival of patients. These downstaging procedures included three-dimensional conformal radiation therapy, trans-arterial chemoembolization, stereotactic body radiation therapy, trans-arterial radioembolization, hepatic arterial infusion chemotherapy and combinations of these therapies. Selection of the optimal downstaging protocol should depend on tumor location, biology and background liver status. The risk factors affecting outcome include pre-downstaging alpha-fetoprotein values, delta alpha-fetoprotein values, disappearance of portal vein tumor thrombosis on imaging and meeting the Milan criteria or not after downstaging. For hepatocellular carcinoma with portal vein tumor thrombosis, downstaging procedure with liver transplantation in mind would be helpful. If the reaction of the downstaged tumor is good, liver transplantation may be performed.

Liver Damage after Transarterial Chemoembolization without Embolizing Agent in Unresectable Hepatocellular Carcinoma

2003 ◽  
Vol 89 (3) ◽  
pp. 285-287 ◽  
Author(s):  
Stefano Puleo ◽  
Letizia Mauro ◽  
Giuseppe Gagliano ◽  
Rosario Lombardo ◽  
Giovanni Li Destri ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Transarterial Chemoembolization ◽  
Alpha Fetoprotein ◽  
Total Serum ◽  
Advanced Hepatocellular Carcinoma ◽  
Significant Finding ◽  
Safe Procedure ◽  
Hepatic Functional Reserve ◽  
Neoplastic Tissue ◽  
Functional Reserve

Aim and Background Transarterial chemoembolization represents a therapy for hepatocellular carcinoma, but in cirrhotic patients affected by large or multifocal HCC with poor hepatic functional reserve, the procedure can damage normal parenchyma. We analyzed the effects on hepatic function of a modified chemoembolization consisting of ethiodized oil (Lipiodol Ultra Fluid) and epirubicin without gelatine sponge (C-LIP). Methods Of 90 patients with hepatocellular carcinoma observed from January 1995 to December 1999, 16 with a diagnosis of advanced (large or multifocal) disease underwent 19 C-LIP. The 30th post-C-LIP day was considered as a checkpoint of the biochemical parameters for a possible hepatic failure. The value of alpha-fetoprotein and the clinical finding of ascites were also considered after 30 days. Results Postoperative values of serum aspartate aminotrasferases, as well as alanine aminotransferase, were significantly higher than preoperative values (P = 0.002 and P = 0.019, respectively) (Table 1). In all patients, there was a significant increase in postoperative total serum bilirubin (P = 0.003). Statistical analysis showed a significant finding of postoperative ascites (P = 0.035) and the effectiveness of C-LIP on neoplastic tissue by a decrease of alpha-fetoprotein values at 30 days (P = 0.067). Conclusions Transcatether arterial chemoembolization could represent an effective therapy against multifocal or advanced hepatocellular carcinoma, and its effectiveness is probably not decreased by using a modified procedure without embolizing agent (C-LIP). However, even when performing such a safe procedure, the hepatic functional reserve of the individual patient needs to be accurately evaluated in order to avoid liver failure.

Alpha-Fetoprotein Response in Advanced Hepatocellular Carcinoma Receiving Cytostatic Agent

2009 ◽  
Vol 27 (36) ◽  
pp. e271-e271 ◽  
Author(s):  
Li-Tzong Chen ◽  
Her-Shyong Shiah ◽  
Yee Chao ◽  
Jang-Yang Chang ◽  
Li-Ting Cheng ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Alpha Fetoprotein ◽  
Advanced Hepatocellular Carcinoma ◽  
Cytostatic Agent

scholarly journals alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma

2005 ◽  
Vol 22 (3) ◽  
pp. 217-226 ◽  
Author(s):  
L.-T. CHEN ◽  
T.-W. LIU ◽  
Y. CHAO ◽  
H.-S. SHIAH ◽  
J.-Y. CHANG ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Alpha Fetoprotein ◽  
Advanced Hepatocellular Carcinoma

Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma

2012 ◽  
Vol 57 (1) ◽  
pp. 101-107 ◽  
Author(s):  
Nicola Personeni ◽  
Silvia Bozzarelli ◽  
Tiziana Pressiani ◽  
Lorenza Rimassa ◽  
Maria Chiara Tronconi ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Alpha Fetoprotein ◽  
Advanced Hepatocellular Carcinoma
Sign in / Sign up

Export Citation Format

Share Document